The CDC has made its annual flu shot recommendations for health professionals ahead of flu season.
They again underscore the importance of flu shots: Preliminary estimates show that last season, people vaccinated against the flu were about 40% to 70% less likely to be hospitalized because of flu illness or related complications.
U.S. COVID cases are once again at a high plateau, climbing to heights not seen since late last winter.
With all eyes on the new, highly mutated COVID variant “Pirola” BA.2.86 and respiratory virus season on its way, is it time to start masking again?
The omicron subvariants that have become dominant in recent months present a serious threat to the effectiveness of the new boosters, render antibody treatments ineffective and could cause a surge of breakthrough infections, according to a new study.
A new omicron subvariant has been detected in the U.K. as the country faces a renewed surge in Covid-19 hospitalizations.
The XE variant, as it is known, has so far been detected in 637 patients nationwide, according to the latest statistics from the U.K. Health Security Agency, which said there is currently not enough evidence to draw conclusions on its transmissibility or severity.
Experts warn that another coronavirus wave may be imminent in the United States, fueled by a more contagious Omicron subvariant that is spreading rapidly in Europe, though they said the trend was more a cause for caution than alarm.
The Omicron variant this month began its second sweep through Europe, where past virus surges have been a harbinger of what was to come in the United States. Many countries thought they were free of the worst of Covid and raced to lift restrictions in February and March, but a highly transmissible Omicron subvariant, BA.2, is contributing to the new surge.
As Covid-19 cases continue to fall and state and local governments lift remaining pandemic restrictions, many offices are asking employees to return to in-person work.
We know that 60% of workers with jobs that can be done from home say they’d like to work from home most or all of the time when the pandemic is over, if given the choice, according to a new Pew Research Center survey. That’s up from 54% in 2020.
But what if you want to go back or are required to go back into the office? How should people consider the safety of going back to the office and other in-person work environments?
Several rapid antigen tests that are widely used in the United States — Abbott BinaxNow, BD Veritor At-Home and Quidel QuickVue — are effective in detecting the Omicron variant of the coronavirus, according to a new real-world study that eases concerns about possible false negative test results.
Decisions on vaccination policies—whether to require them for employees, especially after the Supreme Court blocked the rule that large companies would have to mandate vaccines for their workers—have been among employers’ biggest and most complex problems in recent months.
Now they’re faced with a new variable: whether to require booster shots.
The Food and Drug Administration (FDA) announced a recall of the STANDARD Q COVID-19 Ag Home Test because of its illegal importation to the United States, but Americans still have 17 other choices for FDA-authorized rapid at-home tests.
At-home COVID-19 tests are considered a critical part of America’s response to the pandemic because they help alleviate strain on health care systems and pharmacies during surges in cases. However, officials warned against the use of unauthorized tests out of concerns that the results aren’t accurate, and the FDA advised people to throw out STANDARD Q COVID-19 Ag Home Test kits because it only provides an “initial screening test result.”
SD Biosensor, Inc., a global in-vitro diagnostics company, is voluntarily recalling its STANDARD Q COVID-19 Ag Home Test in the United States, due to confirmed reports that the test kits were illegally imported into the United States. The STANDARD Q COVID-19 Ag Home Test is not authorized, cleared or approved by the U.S. Food and Drug Administration (FDA) for distribution or use in the United States. While there is no known distribution of these tests directly to consumers, SD Biosensor, Inc. is issuing this voluntary recall out of an abundance of caution.